Volatility Spike After Extended Uptrend – Early Signs of Distribution?

This chart reflects a stock that was in a sustained uptrend but is now showing sharp rejection near highs, hinting at a potential shift in structure. From an Elliott Wave standpoint, the prior rally appears to have completed a 5-wave impulsive structure, with the recent sharp red candle suggesting the possible start of an ABC corrective phase. The rejection from the ₹2,020 zone indicates that Wave 5 may have topped out, and the market could now be transitioning into Wave A of correction. On the momentum front, such a strong bearish candle after a prolonged rise often aligns with a bearish MACD divergence in the background. While price made higher highs, momentum likely weakened, and this breakdown candle confirms that sellers have started gaining control. Looking at AVWAP, if anchored from the recent swing low of the uptrend, price has now broken below the AVWAP, which is a critical signal. This indicates that the average buyer in the recent rally is now under pressure. The AVWAP zone around ₹1,980–₹2,000 is likely to act as immediate resistance on pullbacks. From a fundamental perspective, the company remains reasonably stable with: Consistent revenue visibility in the pharma space Decent margins compared to industry averages Ongoing product pipeline acting as a long-term tailwind However, in the short term, price action is diverging from fundamentals, which is common during corrective phases. Conclusion: The structure suggests a shift from bullish continuation to short-term correction or consolidation. A pullback towards ₹1,900–₹1,920 is possible if weakness persists. Any bounce towards ₹1,980–₹2,000 should be watched closely for selling pressure unless price reclaims and sustains above this zone convincingly.